Meisi Yan

2.0k total citations · 2 hit papers
21 papers, 1.2k citations indexed

About

Meisi Yan is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Meisi Yan has authored 21 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Molecular Biology, 10 papers in Oncology and 8 papers in Immunology. Recurrent topics in Meisi Yan's work include Cancer Immunotherapy and Biomarkers (4 papers), Cancer Cells and Metastasis (4 papers) and Immunotherapy and Immune Responses (4 papers). Meisi Yan is often cited by papers focused on Cancer Immunotherapy and Biomarkers (4 papers), Cancer Cells and Metastasis (4 papers) and Immunotherapy and Immune Responses (4 papers). Meisi Yan collaborates with scholars based in China, United States and Taiwan. Meisi Yan's co-authors include Jennifer L. Hsu, Mien‐Chie Hung, Jung-Mao Hsu, Jun Yao, Chao‐Kai Chou, Dihua Yu, Heng‐Huan Lee, Yongkun Wei, Gabriel N. Hortobágyi and Hui Li and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Investigation and Nature Communications.

In The Last Decade

Meisi Yan

20 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy

2021 405 citations Ri‐Yao Yang, Linlin Sun et al. Nature Communications profile →
TYRO3 induces anti–PD-1/PD-L1 therapy resistance by limiting innate immunity and tumoral ferroptosis

2021 255 citations Zhou Jiang, Seung-Oe Lim et al. Journal of Clinical Investigation profile →

Peers

Meisi Yan

ONCOL

IMMUN

PRM

David S.M. Lee United States

Zheng Lv China

Laura Stanbery United States

Adam Cooper Australia

Junshang Ge China

Jonathan F. Anker United States

Dongli Yue China

Miriam Redrado Spain

Marsela Braunstein Canada

David S.M. Lee United States

Meisi Yan

711 ×1.2

672 ×1.2

ONCOL

595 ×1.1

IMMUN

416 ×1.4

209 ×0.7

PRM

Citations per year, relative to Meisi Yan Meisi Yan (= 1×) peers David S.M. Lee

Countries citing papers authored by Meisi Yan

Since Specialization

Citations

This map shows the geographic impact of Meisi Yan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Meisi Yan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Meisi Yan more than expected).

Fields of papers citing papers by Meisi Yan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Meisi Yan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Meisi Yan. The network helps show where Meisi Yan may publish in the future.

Co-authorship network of co-authors of Meisi Yan

This figure shows the co-authorship network connecting the top 25 collaborators of Meisi Yan. A scholar is included among the top collaborators of Meisi Yan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Meisi Yan. Meisi Yan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wu, Hao, Xinghua Zhang, Shengye Jin, et al.. (2025). The combination of flaxseed lignans and PD-1/ PD-L1 inhibitor inhibits breast cancer growth via modulating gut microbiome and host immunity. Drug Resistance Updates. 80. 101222–101222. 12 indexed citations

Zhao, Li, Meisi Yan, Shengye Jin, et al.. (2025). H4K79 and H4K91 histone lactylation, newly identified lactylation sites enriched in breast cancer. Journal of Experimental & Clinical Cancer Research. 44(1). 252–252. 2 indexed citations

Zhang, Wanting, He Ren, Yilin Liu, et al.. (2025). The tumor microbiome in cancer progression: mechanisms and therapeutic potential. Molecular Cancer. 24(1). 195–195. 4 indexed citations

Chen, Xiaohan, Jinfeng Yi, Lili Xie, et al.. (2024). Integration of transcriptomics and machine learning for insights into breast cancer: exploring lipid metabolism and immune interactions. Frontiers in Immunology. 15. 1470167–1470167. 3 indexed citations

Yu, Lu, et al.. (2023). The combination of the HDAC1 inhibitor SAHA and doxorubicin has synergic efficacy in triple negative breast cancer in vivo. Pharmacological Research. 196. 106926–106926. 13 indexed citations

Wang, Wenzheng, Yingqiang Fu, Xin Li, et al.. (2023). Cancer stem cells promote lymph nodes metastasis of breast cancer by reprogramming tumor microenvironment. Translational Oncology. 35. 101733–101733. 8 indexed citations

Liu, Tong, Cheng Liu, Meisi Yan, et al.. (2022). Single cell profiling of primary and paired metastatic lymph node tumors in breast cancer patients. Nature Communications. 13(1). 6823–6823. 54 indexed citations

Jiao, Shiping, Qing Xiong, Meisi Yan, et al.. (2022). Intratumor expanded T cell clones can be non-sentinel lymph node derived in breast cancer revealed by single-cell immune profiling. Journal for ImmunoTherapy of Cancer. 10(1). e003325–e003325. 13 indexed citations

Jiang, Zhou, Seung-Oe Lim, Meisi Yan, et al.. (2021). TYRO3 induces anti–PD-1/PD-L1 therapy resistance by limiting innate immunity and tumoral ferroptosis. Journal of Clinical Investigation. 131(8). 255 indexed citations breakdown →

10.

Cha, Jong‐Ho, et al.. (2021). ATXN7L3B promotes hepatocellular carcinoma stemness and is downregulated by metformin. Biochemical and Biophysical Research Communications. 573. 1–8. 6 indexed citations

11.

Yang, Ri‐Yao, Linlin Sun, Ching-Fei Li, et al.. (2021). Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy. Nature Communications. 12(1). 832–832. 405 indexed citations breakdown →

12.

Liu, Chunxiao, Zhengyu Zha, Chenhao Zhou, et al.. (2020). Ribonuclease 7-driven activation of ROS1 is a potential therapeutic target in hepatocellular carcinoma. Journal of Hepatology. 74(4). 907–918. 21 indexed citations

13.

Yan, Meisi, Leiguang Ye, Xinxin Feng, et al.. (2020). MicroRNA-590-3p inhibits invasion and metastasis in triple-negative breast cancer by targeting Slug.. PubMed. 10(3). 965–974. 18 indexed citations

14.

Lee, Heng‐Huan, Ying‐Nai Wang, Weiya Xia, et al.. (2019). Removal of N-Linked Glycosylation Enhances PD-L1 Detection and Predicts Anti-PD-1/PD-L1 Therapeutic Efficacy. Cancer Cell. 36(2). 168–178.e4. 282 indexed citations

15.

Yan, Meisi, Jinsong Wang, Yanlv Ren, et al.. (2019). Over-expression of FSIP1 promotes breast cancer progression and confers resistance to docetaxel via MRP1 stabilization. Cell Death and Disease. 10(3). 204–204. 20 indexed citations

16.

Wang, Xiuli, Duanyang Liu, Lei Zhang, et al.. (2018). Relationship between infiltrating lymphocytes in cancerous ascites and dysfunction of Cajal mesenchymal cells in the small intestine.. PubMed. 11(4). 2201–2213.

17.

Liu, Tong, Hao Zhang, Li Sun, et al.. (2017). FSIP1 binds HER2 directly to regulate breast cancer growth and invasiveness. Proceedings of the National Academy of Sciences. 114(29). 7683–7688. 25 indexed citations

18.

Yan, Meisi, Zheng‐Xiang Li, Dandan Tong, et al.. (2016). miR-136 suppresses tumor invasion and metastasis by targeting RASAL2 in triple-negative breast cancer. Oncology Reports. 36(1). 65–71. 69 indexed citations

19.

Yan, Meisi, Lei Zhang, Yiqi Wu, et al.. (2016). Increased expression of kindlin‐2 is correlated with hematogenous metastasis and poor prognosis in patients with clear cell renal cell carcinoma. FEBS Open Bio. 6(7). 660–665. 13 indexed citations

20.

Yan, Meisi, et al.. (2014). Association of insulin gene variable number of tandem repeats regulatory polymorphism with polycystic ovary syndrome. Human Immunology. 75(10). 1047–1052. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact